
June 5 (Reuters) - Telomir Pharmaceuticals Inc TELO.O:
TELOMIR PHARMACEUTICALS-NEW DATA FROM PRECLINICAL STUDY OF ITS LEAD COMPOUND, TELOMIR-1, IN VALIDATED ANIMAL MODEL OF WERNER SYNDROME
TELOMIR PHARMACEUTICALS- ANNOUNCES TELOMIR-1 RESETS EPIGENETIC CLOCK, REVERSES DNA METHYLATION - SEC FILING
Source text: [ID:n0001641172-25-013711]